Stock Events

Stock Events

Solid Biosciences

€25.78

59

+€0+0% Monday 20:00

Statistics

Day High

1.72

Day Low

1.72

52W High

25.78

52W Low

1.72

Volume

300

Avg. Volume

0

Mkt Cap

0

P/E Ratio

-

Dividend Yield

-

Dividend

-

Upcoming

Earnings

8MayExpected

Q4 2025

Next

-0.46

-0.43

-0.4

-0.37

Expected EPS

-0.36941119625

Actual EPS

N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow B6C.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Sarepta Therapeutics

Sarepta Therapeutics focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases, including Duchenne muscular dystrophy (DMD), directly competing with Solid Biosciences' gene therapy approaches for DMD.

PTC Therapeutics

PTC Therapeutics is involved in the development of genetically targeted therapies for the treatment of rare diseases, including DMD, positioning it as a competitor in the same therapeutic area as Solid Biosciences.

Biomarin Pharmaceutical

BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, including therapies for DMD, making it a direct competitor in the rare disease space.

Pfizer is engaged in the discovery, development, manufacture, and sale of healthcare products, including gene therapies for rare diseases. Its broad focus on gene therapy research can potentially compete with Solid Biosciences' DMD treatments.

Sangamo Therapeutics

Sangamo Therapeutics focuses on genomic medicine, including gene therapy, gene editing, and gene regulation, to develop treatments for DMD among other diseases, positioning it as a competitor in the gene therapy space.

Dyadic International DE

Dyadic International leverages its proprietary C1 gene expression platform to develop and produce biologic vaccines and drugs at flexible scales, including potential treatments for rare diseases, which may compete with Solid Biosciences' therapeutic approaches.

Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical focuses on the development of novel products for serious rare and ultra-rare genetic diseases, including muscle-related disorders, which could compete with Solid Biosciences' pipeline.

Abeona Therapeutics

Abeona Therapeutics is focused on developing gene and cell therapies for life-threatening rare genetic diseases, including DMD, making it a direct competitor in the gene therapy market.

Novartis is a global healthcare company that, through its acquisition of AveXis, has entered the gene therapy market for spinal muscular atrophy and is exploring treatments for other genetic disorders, potentially competing with Solid Biosciences in the broader gene therapy market.

About

Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Show more...

CEO

Mr. Ian F. Smith A.C.A., C.P.A.

Employees

100

Country

United States

ISIN

US83422E2046

Listings

0 Comments

Share your thoughts

FAQ

What is Solid Biosciences stock price today?▼

The current price of B6C.MU is €25.78 EUR — it has increased by +0% in the past 24 hours. Watch Solid Biosciences stock price performance more closely on the chart.

What is Solid Biosciences stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Solid Biosciences stocks are traded under the ticker B6C.MU.

Is Solid Biosciences stock price growing?▼

B6C.MU stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Solid Biosciences has showed a +0% increase.

When is the next Solid Biosciences earnings date?▼

Solid Biosciences is going to release the next earnings report on May 08, 2026.

What were Solid Biosciences earnings last quarter?▼

B6C.MU earnings for the last quarter are -0.46 EUR per share, whereas the estimation was -0.45 EUR resulting in a -2.18% surprise. The estimated earnings for the next quarter are N/A EUR per share.

How many employees does Solid Biosciences have?▼

As of May 06, 2026, the company has 100 employees.

In which sector is Solid Biosciences located?▼

Solid Biosciences operates in the Health & Wellness sector.

When did Solid Biosciences complete a stock split?▼

Solid Biosciences has not had any recent stock splits.

Where is Solid Biosciences headquartered?▼

Solid Biosciences is headquartered in Charlestown, United States.